

BREATHTEC BIOMEDICAL INC.

Suite 890, 789 West Pender Street
Vancouver, British Columbia, Canada V6C 1H2

Breathtec Biomedical Announces Prof. Hossam Haick as Consultant

--Highly Recognized and Awarded Expert to Guide Trials and Approvals Process of NA-NOSE Technology.

VANCOUVER, BC--(Marketwired - Apr 19, 2016) - [Breathtec Biomedical Inc.](#) (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTC PINK: BTHCF) (the "**Company**" or "**Breathtec**"), a medical diagnostics company focused on developing, and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases is pleased to announce that Professor Hossam Haick of Technion University and the developer of the NA-NOSE disease detection sensors has joined Breathtec Biomedical as consultant. Prof. Haick will guide the company's development of the NA-NOSE disease detection system and design the clinical trials to be undertaken by the company.

As recently announced, Breathtec entered into a licensing agreement on April 11, 2016 with the Technion Research and Development Foundation Ltd., an Israeli private company and wholly-owned subsidiary of the Technion – Israel Institute of Technology, with respect to a non-exclusive license to certain Technion patents and related know-how in connection with the NA-NOSE disease detection sensors and the detection of the following indications from exhaled breath: Streptococcus; Methicillin resistant (MRSA); Staphylococcus; Enterococcus; Vancomycin resistant (VRE); Pneumococcus; Hemophilus influenza (HiB); Chickenpox; and the common cold.

Prof. Hossam Haick of the Technion Institute

Dr. Haick's groundbreaking research has led to the creation of a technology that can smell out cancer and other diseases, has recently been acclaimed as one of the world's most "Good" people, as noted by [GOOD Magazine](#), an international publication that recognizes researchers for the benefits of their work for humanity. According to the magazine publishers, Haick is one of the 100 most influential people in the world who are changing the world in a positive manner. The GOOD 100 are "spearheading change" in the areas of science, education, and business, said the magazine, and Haick, among them, "refuses to accept the existing reality as the end of the story. Not one of the 100 people we have chosen operates out of a desire for fame -- which is precisely why it is important to recognize their activity."

Besides the GOOD recognition, Dr. Haick was also recently presented with the [Humboldt Research Award](#), which recognizes top research done throughout the world in cooperation with research institutes in Germany. Awarded by the Alexander von Humboldt Foundation, the prize is given to prominent researchers who have significantly influenced their fields of study in cooperation with research institutes in Germany. It is granted in recognition of a researcher's achievements as a whole -- discoveries, theories, and insights.

Dr. Haick is best known for developing the [NA-NOSE technology](#) that can be used to detect cancer by mechanically "smelling" elements in the breath of potential sufferers. Cancer tumors produce chemicals called volatile organic compounds (VOCs), which easily evaporate into the air and produce a discernible scent profile. Haick's Na-NOSE chip detects the unique "signature" of VOCs in exhaled breath. In four out of five cases, the device differentiated between benign and malignant lung lesions and even different cancer subtypes.

Mr. Kal Malhi, President of Breathtec Biomedical, states, "We are extremely grateful to have acquired the NA-NOSE technology and the guidance of Prof. Haick. He is truly a pioneer in the field of breath testing and has achieved some amazing results in the field. Breathtec is excited to partner with Prof. Haick in order to commercialize breath testing technology and prepare it for a global marketplace."

For more information, please visit: www.breathtecbiomedical.com.

ON BEHALF OF THE BOARD

"Kal Malhi"

President & Director

For further information, please contact:

CORE Capital Partners

Telephone: 604-566-9233

Email: investors@ccpartnersinc.com

Website: www.breathtecbiomedical.com

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.